Clinical Trial Update: Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1 [Phase 4]

View source ↗

Summary

This clinical trial update reports that the Phase 4 study of simeprevir plus sofosbuvir for chronic hepatitis C genotype 1 has been withdrawn. The trial assesse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Olysio (Simeprevir)
• Sovaldi (Sofosbuvir)

Snippet

Sponsor: Stanford University | Conditions: PT-NANBH | Phase 4 | Status: WITHDRAWN